Address: Level 3 21 Solent Circuit BAULKHAM HILLS NSW 2153 AUSTRALIA
,Australia
Tel: 1800 224 321
Web: http://www.novonordisk.com.au/documents/home_page/document/index.asp
At Novo Nordisk, we strive to be the world’s leading diabetes care company, and each of us takes this vision personally. Our highest priority is the health and well being of people living with diabetes. We respect their many lifestyles and individual needs and develop our therapies with those differences in mind.
Through intensive research, Novo Nordisk has created innovative insulin delivery systems as well as disposable needles that were designed to help reduce pain and fear of injection. Using recombinant technology, we have developed novel insulin and insulin analog formulations. We also offer patient education programs, continuing medical education for healthcare professionals, and more, as we strive to meet the individual needs of our customers!
In addition, we hold a leading position in other therapeutic areas, such as coagulation disorders, growth hormone disorders, and hormone therapy for women.
Novo Nordisk has affiliate offices in 81 countries and approximately 27,000 full-time employees worldwide. We reach out to 179 countries around the world with our products and programs. We operate manufacturing facilities in six countries, including the United States.
Novo Nordisk has a comprehensive range of products relating to diabetes, haemostasis, growth and the menopause.
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the…
The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to…
Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the…
The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
See our Cookie Privacy Policy Here
